Sciencast Management LP bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 4,263 shares of the medical research company's stock, valued at approximately $838,000.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Synergy Asset Management LLC purchased a new stake in shares of IQVIA in the fourth quarter valued at $33,000. Avior Wealth Management LLC increased its stake in shares of IQVIA by 117.6% during the 3rd quarter. Avior Wealth Management LLC now owns 161 shares of the medical research company's stock valued at $38,000 after acquiring an additional 87 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in shares of IQVIA during the 4th quarter worth about $44,000. Versant Capital Management Inc grew its holdings in IQVIA by 46.0% in the fourth quarter. Versant Capital Management Inc now owns 295 shares of the medical research company's stock valued at $58,000 after purchasing an additional 93 shares during the period. Finally, SBI Securities Co. Ltd. acquired a new position in IQVIA during the fourth quarter worth approximately $60,000. 89.62% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
A number of equities analysts have weighed in on IQV shares. JPMorgan Chase & Co. decreased their price target on shares of IQVIA from $240.00 to $232.00 and set an "overweight" rating on the stock in a report on Tuesday, February 18th. Stifel Nicolaus lowered their price target on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Bank of America reduced their price objective on IQVIA from $255.00 to $235.00 and set a "buy" rating on the stock in a research note on Friday, December 13th. Barclays dropped their target price on shares of IQVIA from $255.00 to $235.00 and set an "overweight" rating for the company in a research report on Monday, February 3rd. Finally, Morgan Stanley lifted their price target on shares of IQVIA from $245.00 to $250.00 and gave the company an "overweight" rating in a research report on Tuesday, February 11th. Five research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $249.05.
Check Out Our Latest Stock Report on IQV
IQVIA Stock Down 0.8 %
Shares of IQV traded down $1.48 during trading on Wednesday, reaching $179.91. The company's stock had a trading volume of 1,316,674 shares, compared to its average volume of 1,244,298. The company has a market cap of $31.72 billion, a price-to-earnings ratio of 23.99, a P/E/G ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. The company has a fifty day moving average of $193.92 and a two-hundred day moving average of $207.10. IQVIA Holdings Inc. has a twelve month low of $179.12 and a twelve month high of $253.84.
IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.
IQVIA Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
